Blade Air Mobility Lifts Guidance After Strong Quarter

Blade Air Mobility, Inc. ((SRTA)) has held its Q4 earnings call. Read on for the main highlights of the call.

Blade Air Mobility’s latest earnings call painted a picture of a company gaining real momentum, balancing strong organic growth with improving profitability and a fortified balance sheet. Management acknowledged some near-term noise from integration costs, cash flow timing issues, and a one-off aircraft write-down, but emphasized that these are transient against rising margins, upgraded guidance, and a pipeline of M&A-driven upside.

Surging Organic Logistics Growth Fuels Top-Line Momentum

Blade reported standout organic performance in its logistics segment, with Q4 logistics revenue rising 35.3% year over year to $49.2 million from $36.4 million. Management highlighted that overall organic growth in the quarter was also about 35%, supporting a strong finish to the year and providing a solid base of sustained volume heading into 2026.

Full-Year Results Exceed Prior Guidance Ranges

For the full year 2025, Blade generated $197.1 million in revenue and $14.1 million in adjusted EBITDA, beating the high end of its previous guidance ranges on both metrics. The outperformance was primarily driven by the robust Q4, showing that underlying demand and execution are tracking ahead of earlier expectations.

Profitability Metrics Show Sharp Improvement

Profitability made a notable step up in Q4 as gross profit nearly doubled, rising 90% to $14.4 million versus $7.6 million a year earlier. The company’s blended gross margin improved about 80 basis points to 21.6%, while logistics gross profit climbed 39.5% to $10.6 million with logistics gross margin up roughly 70 basis points to 21.5%.

Adjusted EBITDA Rebounds With Expanding Margins

Adjusted EBITDA in Q4 2025 recovered strongly to $7.0 million, a sharp improvement from $1.1 million in the prior-year period and $4.2 million in the previous quarter. The Q4 adjusted EBITDA margin reached 10.4%, and management raised 2026 adjusted EBITDA guidance to a range of $29 million to $33 million from $28 million to $32 million, underscoring confidence in continued margin expansion.

Higher 2026 Revenue Targets and Balance-Sheet Strength

Blade lifted its 2026 revenue guidance to $260 million to $275 million, up from $255 million to $270 million, reflecting stronger demand and integration benefits. The company ended Q4 with no debt and about $61 million in cash and short-term investments and reiterated its target for free cash flow before aircraft and engine purchases of $15 million to $22 million.

Keystone Integration Builds a Scalable M&A Platform

The first full quarter after closing the Keystone deal delivered $17.6 million of clinical revenue in Q4, including $7.8 million from transplant clinical and $9.8 million from other clinical services. Management framed Keystone as proof of its acquisition playbook and said it expects continued M&A to drive at least 30% annual adjusted EBITDA growth, supported by a new undrawn $30 million asset-based credit facility that can be upsized to $50 million.

Regulatory Tailwinds and Differentiated Service Capabilities

Management pointed to proposed regulatory actions that could boost demand, particularly incentives for DCD donors and momentum around continuous distribution for lungs that align with Blade’s NRP and DCD strengths. About 20% of revenue now comes from OPOs, with Tier 1 OPO customers generating 2.4 times the revenue of Tier 3, and a recent decertification and absorption of an underperforming OPO has already translated into new business wins.

Targeted Fleet Ownership Enhances Commercial Leverage

Blade continues to run an asset-light model but complements it with about 30 dedicated or owned aircraft, owning only a slice of total capacity to improve control and economics. Management said this limited ownership has helped unlock new contracts and improve negotiations with third-party carriers and plans to add around two more owned aircraft in 2026, with one already acquired and moving through conformity.

Cash Flow Drag From One-Off Charges and Working Capital

Operating cash flow was a negative $8.3 million in Q4, creating a $15.3 million gap versus adjusted EBITDA that management largely attributed to nonrecurring items and working capital. Roughly $9.6 million came from a legacy legal settlement, transaction fees, and other one-offs, while about $5.7 million reflected a working capital build tied to integration delays and strong year-end logistics growth.

Nonrecurring Costs and Elevated SG&A from Keystone

Adjusted SG&A climbed to $8.9 million in Q4 from $7.5 million in Q3 2025, an increase of about 18.7%, mainly due to a full quarter of Keystone-related costs and integration spending. These nonrecurring items, totaling $9.6 million, weighed on cash flow but are not expected to be a structural drag as integration progresses and synergies begin to show through.

Aircraft Corrosion Event Highlights Asset Risk

During the quarter, Blade discovered corrosion on one owned aircraft and decided to part out the plane, recording a book loss of $1.7 million and estimating the economic loss at around $400,000. After inspecting roughly two-thirds of the fleet with no similar issues found, management characterized the event as isolated but a reminder of the inherent maintenance risk in aircraft ownership.

Seasonal and Mix Headwinds to Near-Term Performance

Looking to Q1 2026, the company warned of a modest sequential revenue decline relative to Q4 2025 and an expected roughly 100-basis-point drop in adjusted EBITDA margin. Management cited seasonal patterns, a shift toward shorter trips, and weather disruptions in the Northeast as the primary drivers but expects these effects to ease as the year progresses.

Industry Donor Dynamics and Regulatory Uncertainty

While Blade is growing, the broader U.S. transplant market saw a flattening in organ donors and NRP donors during 2025 amid regulatory and media scrutiny. Management also flagged uncertainty around the timing of continuous distribution rollouts for hearts and livers, which could delay some assumed market expansion even though the company believes its capabilities position it well for eventual adoption.

Contingent Obligations and Available Liquidity Firepower

The capital structure includes a contingent earn-out related to Joby of up to $45 million, with a portion tied to performance and the balance linked to employee retention. At the same time, Blade highlighted that its $30 million asset-based facility is fully undrawn, its aircraft are unencumbered, and it retains significant liquidity to fund growth and acquisitions without compromising its asset-light strategy.

Metric Changes Affect Historical Margin Comparability

Blade’s shift from its prior “flight profit” measure to GAAP gross profit has reclassified some expenses from SG&A into cost of sales, reducing reported logistics gross margins by roughly 200 to 250 basis points versus its old medical flight margin metric. Management emphasized that this has no impact on adjusted EBITDA but does make comparisons to historical public margin disclosures less straightforward for investors tracking trends.

Guidance and Outlook Emphasize Growth and Discipline

Management’s updated outlook calls for 2026 revenue of $260 million to $275 million and adjusted EBITDA of $29 million to $33 million, with free cash flow before aircraft and engine purchases of $15 million to $22 million and at least 30% average adjusted EBITDA growth driven by acquisitions. They expect Q1 2026 to be softer sequentially on revenue and margin but see revenue and profitability improving from Q2 onward as new customers ramp up, supported by about $61 million of cash, no debt, an undrawn credit facility, and a lean fleet strategy.

Blade’s earnings call underscored a company transitioning from top-line proof of concept to a more profitable, scaled platform in medical logistics and air mobility. For investors, the story hinges on sustained organic growth, disciplined M&A, and managing near-term integration and cash flow noise, with upgraded guidance and a strong balance sheet suggesting the risk-reward remains tilted positively.